Valuation dashboard for Belite Bio, Inc (BLTE) with P/E N/A, P/B 8.75, EV/EBITDA -64.97 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $169.21, BLTE has negative trailing earnings (P/E not meaningful) and an ROE of -10.07%. Market capitalisation stands at $6.8B.
Balance sheet quality for BLTE: current ratio of 50.0. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 8.75 |
| EV / EBITDA | -64.97 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| BLTE | Belite Bio, Inc | $6.8B | 8.75 | -10.1% | |
| PRAX | Praxis Precision Medicines, Inc. | $8.7B | 6.80 | -34.1% | |
| MIRM | Mirum Pharmaceuticals, Inc. | $5.9B | -410.2% | ||
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.0B | 7.52 | -44.2% | |
| LGND | Ligand Pharmaceuticals Incorporated | $5.7B | 27.49 | 5.71 | |
| ACAD | ACADIA Pharmaceuticals Inc. | $4.8B | 12.10 | 3.57 | 32.4% |
| DYN | Dyne Therapeutics, Inc. | $3.4B | 4.20 | -64.3% | |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.3B | 116.28 | 15.19 | -8.5% |
Price
| Price | $169.21 |
| Market Cap | $6.8B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -10.07% |
| Return on Invested Capital | -10.92% |
| Return on Assets | -9.94% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACAD · ADMA · ARQT · CRNX · DYN · LGND · MIRM
Explore sector: Healthcare · Biotechnology
More sections of BLTE: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks